Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Summit Therapeutics Inc.

    NASDAQ: SMMT · Real-Time Price · USD
    20.72
    -0.60 (-2.81%)
    At close: Jun 27, 2025, 2:46 PM

    Summit Therapeutics Statistics

    Share Statistics

    Summit Therapeutics has 742.67M shares outstanding. The number of shares has increased by 5.08% in one year.

    Shares Outstanding

    n/a
    		 742.67M

    Shares Change (YoY)

    n/a
    		 5.08%

    Shares Change (QoQ)

    n/a
    		 0.07%

    Owned by Institutions (%)

    n/a
    		 12.75%

    Shares Floating

    n/a
    		 111.44M

    Failed to Deliver (FTD) Shares

    n/a
    		 29,210

    FTD / Avg. Volume

    n/a
    		 0.6%

    Short Selling Information

    The latest short interest is 24.44M, so 3.29% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 24.44M

    Short % of Shares Out

    n/a
    		 3.29%

    Short % of Float

    n/a
    		 20.96%

    Short Ratio (days to cover)

    n/a
    		 6.14

    Valuation Ratios

    The PE ratio is -57.95 and the forward PE ratio is -48.34. Summit Therapeutics's PEG ratio is 0.84.

    PE Ratio

    n/a
    		 -57.95

    Forward PE

    n/a
    		 -48.34

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 7.6

    PB Ratio

    n/a
    		 32.99

    P/FCF Ratio

    n/a
    		 -90.17

    PEG Ratio

    n/a
    		 0.84
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Summit Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 10.15, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 10.15

    Quick Ratio

    n/a
    		 10.15

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.05

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,391,918.24

    Employee Count

    n/a
    		 159

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 170.9% in the last 52 weeks. The beta is -1.05, so Summit Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -1.05

    52-Week Price Change

    n/a
    		 170.9%

    50-Day Moving Average

    n/a
    		 23.49

    200-Day Moving Average

    n/a
    		 21.01

    Relative Strength Index (RSI)

    n/a
    		 49.26

    Average Volume (20 Days)

    n/a
    		 4,837,620

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -15.01M

    Operating Income

    n/a
    		 313K

    Net Income

    n/a
    		 -221.31M

    EBITDA

    n/a
    		 -212.85M

    EBIT

    n/a
    		 -230M

    Earnings Per Share (EPS)

    n/a
    		 -0.31
    Full Income Statement

    Balance Sheet

    The company has 104.86M in cash and 7.22M in debt, giving a net cash position of 97.64M.

    Cash & Cash Equivalents

    n/a
    		 104.86M

    Total Debt

    n/a
    		 7.22M

    Net Cash

    n/a
    		 97.64M

    Retained Earnings

    n/a
    		 -1.21B

    Total Assets

    n/a
    		 383.82M

    Working Capital

    n/a
    		 335.87M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -142.11M and capital expenditures -139K, giving a free cash flow of -142.25M.

    Operating Cash Flow

    n/a
    		 -142.11M

    Capital Expenditures

    n/a
    		 -139K

    Free Cash Flow

    n/a
    		 -142.25M

    FCF Per Share

    n/a
    		 -0.2
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    SMMT does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SMMT is $37.5, which is 75.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $37.5

    Price Target Difference

    n/a
    		 75.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 12
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 288.66

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist